Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

Spleen tyrosine kinase (Syk) signaling is central to phagocytosis‐based, antibody‐mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on‐treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bussel, James, Arnold, Donald M., Grossbard, Elliot, Mayer, Jiří, Treliński, Jacek, Homenda, Wojciech, Hellmann, Andrzej, Windyga, Jerzy, Sivcheva, Liliya, Khalafallah, Alhossain A., Zaja, Francesco, Cooper, Nichola, Markovtsov, Vadim, Zayed, Hany, Duliege, Anne‐Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055608/
https://www.ncbi.nlm.nih.gov/pubmed/29696684
http://dx.doi.org/10.1002/ajh.25125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055608/
https://www.ncbi.nlm.nih.gov/pubmed/29696684
http://dx.doi.org/10.1002/ajh.25125

Ejemplares similares